Quaglino Elena, Rolla Simona, Iezzi Manuela, Spadaro Michela, Musiani Piero, De Giovanni Carla, Lollini Pier Luigi, Lanzardo Stefania, Forni Guido, Sanges Remo, Crispi Stefania, De Luca Pasquale, Calogero Raffaele, Cavallo Federica
Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy.
J Clin Invest. 2004 Mar;113(5):709-17. doi: 10.1172/JCI19850.
While much experimental data shows that vaccination efficiently inhibits a subsequent challenge by a transplantable tumor, its ability to inhibit the progress of autochthonous preneoplastic lesions is virtually unknown. In this article, we show that a combined DNA and cell vaccine persistently inhibits such lesions in a murine HER-2/neu mammary carcinogenesis model. At 10 weeks of age, all of the ten mammary gland samples from HER-2/neu-transgenic mice displayed foci of hyperplasia that progressed to invasive tumors. Vaccination with plasmids coding for the transmembrane and extracellular domain of rat p185neu followed by a boost with rp185neu+ allogeneic cells secreting IFN-gamma kept 48% of mice tumor free. At 22 weeks, their mammary glands were indistinguishable from those of 10-week-old untreated mice. Furthermore, the transcription patterns of the two sets of glands coincided. Of the 12,000 genes analyzed, 17 were differentially expressed and related to the antibody response. The use of B cell knockout mice as well as the concordance of morphologic and gene expression data demonstrated that the Ab response is the main mechanism facilitating tumor growth arrest. This finding suggests that a new way can be found to secure the immunologic control of the progression of HER-2/neu preneoplastic lesions.
虽然许多实验数据表明接种疫苗能有效抑制可移植肿瘤随后引发的攻击,但其抑制自发肿瘤前病变进展的能力实际上尚不清楚。在本文中,我们表明DNA与细胞联合疫苗能在小鼠HER-2/neu乳腺癌发生模型中持续抑制此类病变。10周龄时,来自HER-2/neu转基因小鼠的所有10个乳腺样本均出现了增生灶,并进展为浸润性肿瘤。用编码大鼠p185neu跨膜和胞外结构域的质粒进行接种,随后用分泌IFN-γ的rp185neu + 同种异体细胞加强免疫,使48%的小鼠无肿瘤。在22周时,它们的乳腺与10周龄未处理小鼠的乳腺无法区分。此外,两组腺体的转录模式一致。在分析的12000个基因中,有17个基因差异表达且与抗体反应有关。使用B细胞敲除小鼠以及形态学和基因表达数据的一致性表明,抗体反应是促进肿瘤生长停滞的主要机制。这一发现表明,可以找到一种新方法来确保对HER-2/neu肿瘤前病变进展的免疫控制。